ArticleCancer2025
Racial differences in kidney cancer histology and outcome: A nationwide study from the UroCCR Cohort.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Individual and composite socioeconomic inequalities in diagnosis, treatment, and survival of kidney cancer: a population-based analysis of the SEER database.World journal of urology · 2026Article
- Survival Differences of Localized Papillary Renal Cell Carcinoma in African Americans vs. European Americans.Journal of racial and ethnic health disparities · 2026Article
- Kidney cancer epidemiology in a French Afro-descendant population: high prevalence of papillary renal cell carcinoma.World journal of urology · 2026Article
- Racial differences in kidney cancer histology and outcome: A nationwide study from the UroCCR Cohort.Cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRacial differences in renal cell carcinoma (RCC) have been well described in U.S. cohorts, particularly for common histologic subtypes. However, such differences remain underexplored in European populations, especially for rare RCC subtypes and within universal health care settings. We aimed to characterize racial differences in RCC histology, renal comorbidities, and clinical outcomes in France, and to investigate potential molecular underpinnings.
methodsA total of 9404 patients were analyzed from the UroCCR national registry (1987-2024), including 338 Black and 9066 non-Black individuals with nephrectomy-confirmed diagnoses. Clinical features, histologic subtypes, and outcomes were compared between groups. Transcriptomic differences between Black and White individuals were assessed using publicly available single-nucleus and bulk RNA-sequencing data from nonneoplastic renal tissue.
resultsClear-cell RCC was less common in Black patients (47.6% vs. 68.8%), whereas papillary, translocation, and fumarate hydratase-deficient RCC subtypes, as well as angiomyolipoma, were more prevalent (all odds ratios ≥ 2). Black patients were diagnosed younger, with smaller, earlier-stage tumors, and underwent partial nephrectomy more frequently. No difference in disease-specific survival was observed; however, distant recurrence-free survival was longer in Black patients (hazard ratio, 0.54; p = .019), likely reflecting earlier diagnosis. Race was not associated with survival after adjusting for clinical factors. Transcriptomic profiling revealed upregulation of adipogenic and angiogenic programs in White individuals and enrichment of hemoglobin- and chemokine-related pathways in Black individuals. Limitations include retrospective design and race classification.
conclusionDistinct racial patterns in RCC histology and renal biology may inform subtype susceptibility. These findings support ancestry-informed strategies in RCC diagnosis and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.